Health Care Utilization and Costs in Systemic Therapies for Metastatic Melanoma, 2016-2020
The Oncologist, 2022
A newer generation of cancer drugs, called immune checkpoint inhibitors, has lowered death rates from advanced melanoma but changed how and where patients are treated. This paper documents how health care use and costs shifted across melanoma treatments between 2016 and 2020.
Published · The Oncologist (2022)
With Mollie F. Qian, Nicolas J. Betancourt, Nolan J. Maloney, Kevin A. Nguyen, Sunil A. Reddy, Evan T. Hall, Susan M. Swetter, and Lisa C. Zaba.
Widespread adoption of immune checkpoint inhibitors and targeted therapies for metastatic melanoma has lowered melanoma-related mortality while raising treatment costs. The paper documents how health care utilization varied across systemic, non-adjuvant melanoma treatments between 2016 and 2020.